Molecular Formula | C18H12N4OS |
Molar Mass | 332.38 |
Density | 1.42±0.1 g/cm3(Predicted) |
Melting Point | 209 °C |
Solubility | DMSO (Slightly), Methanol (Slightly) |
Appearance | powder |
Color | faintly yellow to dark yellow |
pKa | 4.14±0.60(Predicted) |
Storage Condition | room temp |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 3.009 ml | 15.043 ml | 30.086 ml |
5 mM | 0.602 ml | 3.009 ml | 6.017 ml |
10 mM | 0.301 ml | 1.504 ml | 3.009 ml |
5 mM | 0.06 ml | 0.301 ml | 0.602 ml |
biological activity | SCR7 pyrazine is a DNA ligase IV inhibitor, it blocks non-homologous end joining (NHEJ) in a Ligase IV-dependent manner. SCR7 pyrazine, also an enhancer of CRISPR/Cas9, increases the efficiency of Cas9-mediated homology-directed repair (HDR). SCR7 pyrazine induces apoptosis and has anti-cancer activity. |
Target | DNA Ligase IV CRISPR/Cas9 |
Cell Line: | MCF7 cells |
Concentration: | 20 μM, 40 μM, 100 μM |
Incubation Time: | 24 hours |
Result: | Showed an increase in levels of gH2AX foci and protein. Significantly reduced breast adenocarcinoma-induced tumor and increased lifespan. |
Animal Model: | BALB/c mice injected with breast adenocarcinoma cells |
Dosage: | 10 mg/kg |
Administration: | Intraperitoneal injection; on alternate days (0, 2, 4, 6, 8, and 10) |